Healthcare entity
regulation accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Of the tracked stories, 1 of 3 also mention AIDS Drug Assistance Program (ADAP), the most common co-covered peer. Each story carries 2.3 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Aug 13, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Of the tracked stories, 1 of 3 also mention AIDS Drug Assistance Program (ADAP), the most common co-covered peer. Each story carries 2.3 original sources on average, compared with 3.7 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 154-day span. At 6.3, the average consequence score sits above the same-window beat average of 6. This profile follows 3 Healthcare stories mentioning Gilead Sciences across the period from March 13, 2026 to August 13, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 751 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Gilead Sciences. Shared-story counts are live from our verified record — not editorial picks.
NPR report details mixed rollout reviews in Uganda
A syndicated story from Kalisizo, Uganda highlights participant Irene's experience, the drug's six-month protection, and ongoing implementation challenges.
Expected Executive Action
The bill moves to the Governor's desk for final signing and fund disbursement.
Legislative Approval
The Florida Legislature approves a stopgap funding bill with bipartisan support.
Waitlist Warnings
Public health advocacy groups warn that thousands could lose access to medication without intervention.
Budget Shortfall Identified
Projections indicate a significant deficit in the ADAP budget for the current fiscal year.
PURPOSE 1 and PURPOSE 2 deliver unprecedented efficacy
An independent monitoring committee concluded lenacapavir was so effective that the randomized phase of both trials was halted early.
A twice-yearly injectable PrEP, lenacapavir showed unprecedented efficacy in the PURPOSE 1 and 2 trials, yet its rollout in Uganda is drawing mixed reviews. For health systems, the drug's adherence-friendly profile must clear delivery, access, and stigma barriers to achieve population-level impact.
Multiple states are implementing restrictive eligibility criteria and waitlists for AIDS Drug Assistance Programs (ADAPs) as rising medication costs outpace funding. These measures threaten to disrupt treatment for thousands of low-income individuals, potentially reversing years of progress in HIV viral suppression.
The Florida Legislature has passed a stopgap measure to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis for thousands of low-income residents. The move addresses a significant budget shortfall that threatened to create waitlists for life-saving antiretroviral medications.
Source: firstcoastnews.com · orlandosentinel.com
Gilead Sciences is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
